Ly-2584702 hydrochloride is a p70S6K selective ATP competitive inhibitor with IC50 of 4 nM.In the S6K1 enzyme assay, the IC50 of LY-2584702 was 2 nM.

LY-2584702 has some activity against the S6K-related kinases MSK2 and RSK at high concentrations (enzyme assay IC50=58-176 nM).?LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner[2].?Proliferation of A549 is significantly inhibited by LY-2584702 ?treating over 24 h at 0.1 μM (P<0.05);?and the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05).?Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549[3].LY-2584702 ?inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC50 of 0.1-0.24 μM[1].?In S6K1 enzyme assay, the IC50 of LY-2584702 ?is 2 nM.?For pS6 inhibition in cells, the IC50=100 nM.

LY-2584702 significantly inhibits tumor growth as a single agent in U87MG glioblastoma and HCT116 colon carcinoma xenograft models at doses of 2.5 mg/kg and 12.5 mg/kg twice daily (BID), achieving noteworthy tumor growth reduction at threshold minimum effective dose 50% (TMED50) of 2.3 mg/kg and TMED90 of 10 mg/kg in the HCT116 model[1]. In vivo studies involving EOMA cells expressing shAkt3 implanted in nu/nu mice show that, when treated with LY-2584702 or Rapamycin for 14 days, LY-2584702 nearly matches Rapamycin in inhibiting S6 phosphorylation, highlighting its potential mechanism of action against tumors. Additionally, while LY-2584702 does not significantly change the growth of pLKO tumors, it considerably reduces tumor growth in shAkt3 expressing tumors after a 14-day treatment period, pointing to the enhanced tumor growth in the absence of Akt3[2].